Non-Alcoholic Steatohepatitis
An advanced form of non-alcoholic fatty liver disease characterized by hepatic inflammation and fibrosis in the absence of significant alcohol consumption.
TL;DR
NASH is the inflammatory form of fatty liver that scars. Vitamin E at 800 IU daily has genuine randomised evidence in non-diabetic patients, but 7-10% weight loss does more than any supplement.
Overview
Non-alcoholic steatohepatitis, increasingly termed metabolic dysfunction-associated steatohepatitis, is the inflammatory subset of fatty liver disease in which hepatocyte ballooning and lobular inflammation accompany fat accumulation. This distinction matters enormously: simple steatosis carries limited hepatic risk, while steatohepatitis progresses to fibrosis, cirrhosis and hepatocellular carcinoma. Fibrosis stage, not the degree of fat or inflammation, is the strongest predictor of liver-related and overall mortality. Diagnosis has moved away from biopsy for most people. Non-invasive scores such as FIB-4 stratify risk cheaply, and transient elastography quantifies stiffness, with biopsy reserved for uncertain cases. Because the disease is metabolic in origin, the interventions with the largest effect are metabolic. Weight loss is dose-dependent and well characterised: around 5% reduces steatosis, 7% resolves steatohepatitis in a substantial proportion, and 10% improves fibrosis. Exercise reduces liver fat even without weight change. GLP-1 receptor agonists and resmetirom have shifted the pharmacological landscape substantially. Among supplements, vitamin E stands out as genuinely evidence-based. The PIVENS trial showed 800 IU daily improved steatohepatitis histology in non-diabetic adults without cirrhosis, which is why guidelines list it. Omega-3 reduces liver fat and triglycerides but does not resolve inflammation. Coffee, notably, associates consistently with less fibrosis.
Common Symptoms
- •Usually no symptoms at all
- •Vague right upper abdominal discomfort
- •Fatigue
- •Incidentally raised liver enzymes
- •Signs of cirrhosis only in advanced disease
Common Causes
- •Insulin resistance
- •Visceral obesity
- •Type 2 diabetes
- •Dyslipidaemia
- •High fructose and ultra-processed intake
- •PNPLA3 and other genetic variants
- •Obstructive sleep apnea
Root Causes
Insulin resistance driving hepatic de novo lipogenesis and free fatty acid flux from adipose tissue, visceral adiposity, type 2 diabetes, atherogenic dyslipidaemia, high fructose intake, genetic variants including PNPLA3 and TM6SF2, obstructive sleep apnea, and gut microbiome-derived endotoxin exposure.
How It's Diagnosed
Diagnostic Markers
- ALT and AST with AST/ALT ratio
- FIB-4 score
- Transient elastography for liver stiffness
- Ultrasound or MRI proton density fat fraction
- HbA1c and fasting insulin
- Lipid panel
- Exclusion of viral, autoimmune and alcohol-related causes
When to See a Doctor
See a doctor for persistently abnormal liver enzymes, or fatty liver found incidentally on imaging, so that fibrosis can be staged. Seek urgent care for jaundice, abdominal swelling, vomiting blood, or confusion, which suggest decompensated cirrhosis.
Supplements Studied For This
Vitamin E
Vitamin E at 800 IU daily improved steatohepatitis histology in non-diabetic adults without cirrhosis — the strongest supplement evidence in this condition.
Omega-3 Fatty Acids
Omega-3 reliably lowers liver fat and triglycerides but has not been shown to resolve inflammation or improve fibrosis.
Diet & Lifestyle
Suggested Pattern
The Mediterranean pattern has the best evidence, reducing liver fat independently of weight loss. Restricting fructose and ultra-processed foods matters more than total fat, and any calorie-deficit approach achieving sustained loss will help.
Supporting Research
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS)
Effects of different natural products in patients with non-alcoholic fatty liver disease - A network meta-analysis of randomized controlled trials
Effect of vitamin D supplementation on various parameters in patients with non-alcoholic fatty liver disease: An updated meta-analysis
Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Association of prebiotic/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials
Frequently Asked Questions
Who It Affects
Fatty liver disease affects roughly 25-30% of adults globally, with steatohepatitis present in around 3-5% and rising alongside obesity and type 2 diabetes.
Quick Facts
- •Fibrosis stage predicts mortality better than inflammation or fat content
- •Around 7-10% weight loss resolves steatohepatitis in many patients
- •Vitamin E 800 IU improved histology in non-diabetic patients in PIVENS
- •Coffee consumption consistently associates with less liver fibrosis
Lifestyle Tips
- •Target 7-10% body weight loss — nothing else matches its effect on histology
- •Exercise regularly even without weight change; it reduces liver fat independently
- •Cut sugar-sweetened drinks and fructose specifically
- •Keep alcohol intake minimal, since it compounds metabolic liver injury
- •Ask for fibrosis staging rather than settling for a fatty liver label
- •Coffee is associated with less fibrosis and is worth keeping
My Notes
Sign in to add personal notes
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.